Currently held
- Agent 17 — 52-Week High Momentumlong60 sh @ $72.67 · stop —+$7.20 unrealized
TECH
Bio-Techne CorpHealth Careinsider_universeLast close $72.80Nov 12, 2026
Day −0.05%
Everything we've seen
- ❖Nov 12, 7:50 AMnewsvia finnhub
CorMedix (CRMD) Reports Q3 Loss, Tops Revenue Estimates
CorMedix (CRMD) delivered earnings and revenue surprises of +55.56% and +3.89%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
- ❖Nov 10, 9:19 PMnewsvia finnhub
Stock Market: Will S&P 500 Open Up or Down Today?
Will S&P 500 open higher? Polymarket odds hit 83% as Wall Street rides a massive tech rally, weighs Iran diplomacy, and eyes a Fed rate hike.
- ❖Nov 10, 7:15 AMnewsvia finnhub
Humacyte, Inc. (HUMA) Reports Q3 Loss, Tops Revenue Estimates
Humacyte, Inc. (HUMA) delivered earnings and revenue surprises of +22.22% and +19.54%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
- ❖Nov 9, 7:50 AMnewsvia finnhub
TECH Q1 Earnings & Revenues Beat, Merck KGaA Merger Deal Advances
Bio-Techne's Q1 fiscal 2027 earnings and revenues beat estimates, driven by Protein Sciences growth, as its merger with Merck KGaA moves closer to completion.
- ❖Nov 9, 7:40 AMnewsvia finnhub
Roivant Sciences Ltd. (ROIV) Reports Q2 Loss, Tops Revenue Estimates
Montes Archimedes Acquisition (ROIV) delivered earnings and revenue surprises of +53.66% and +1,252.37%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
- ❖Nov 4, 2:10 PMnewsvia finnhub
Bio-Techne (TECH), What Is Behind The Fresh Attention Now?
Bio-Techne (TECH) just put investors on notice with a conditional quarterly dividend of $0.08 per share, tied directly to its pending transaction with Merck KGaA, Darmstadt, Germany, and a key November record date. At a share price of US$72.66, Bio-Techne reflects a year-to-date share price return of 21.81%. The 1-year total shareholder return of 19.59% and 3-year total shareholder return of 23.79% sit against a 5-year total shareholder return that has declined 40.78%, suggesting momentum has...
- ❖Nov 3, 8:30 PMnewsvia finnhub
BIO-TECHNE DECLARES DIVIDEND
Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended September 30, 2026. The quarterly dividend will be payable November 23, 2026, to all common shareholders of record at the close of business on November 13, 2026, provided Bio-Techne's previously announced transaction with Merck KGaA, Darmstadt, Germany has not closed on or before the close of business on November 13, 2026. Future cash dividends will b
- ❖Nov 3, 7:15 AMnewsvia finnhub
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q3 Loss, Beats Revenue Estimates
Rhythm Pharmaceuticals (RYTM) delivered earnings and revenue surprises of +10.29% and +9.07%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
- ❖Nov 3, 7:13 AMnewsvia finnhub
2 high-flying stocks worth your attention and 1 we turn down
Expensive stocks often command premium valuations because the market thinks their business models are exceptional. However, the downside is that high expectations are already baked into their prices, leaving little room for error if they stumble even slightly.
- ❖Nov 2, 4:55 PMnewsvia finnhub
CRISPR Therapeutics AG (CRSP) Reports Q3 Loss, Tops Revenue Estimates
CRISPR Therapeutics (CRSP) delivered earnings and revenue surprises of -8.49% and +27.39%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
- ❖Nov 2, 10:00 AMnewsvia finnhub
Stocks rebound as oil prices sink, Anthropic releases Q3 financials: AlphaCheck
Stocks rebounded on Monday following a brutal sell-off in tech.
- ❖Nov 2, 6:44 AMnewsvia finnhub
Bio-Techne's Q1 Earnings on Deck: What's in Store for the Stock?
TECH's Q1 earnings are on deck, with revenues and EPS growth expected as investors weigh segment performance and the pending $11.3 billion acquisition.
- ▣Nov 1, 7:00 PMjournalrotation
Agent 17 — 52-Week High Momentum closed long 64 @ $72.67 (+$17.28)
52-Week High monthly rebalance. Position retained in target set; re-entered at equal weight.
- ❖Oct 29, 9:53 AMnewsvia finnhub
Alphabet tumbles, software and cybersecurity stocks sink as earnings disappoint: AlphaCheck
Tech stocks declined on Thursday as shares of Alphabet plunged and software and cybersecurity stocks tumbled.
- ❖Oct 28, 10:42 AMnewsvia finnhub
Conestoga SMid Cap Composite Q3 2026 Portfolio Activity
Conestoga added to positions on twelve occasions and trimmed stocks on thirteen occasions during 3Q26.
- ❖Oct 26, 2:30 PMnewsvia finnhub
1 healthcare stock for long-term investors and 2 we ignore
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have not only realized strong financial performance but also propelled the broader industry’s returns as healthcare stocks have gained 31.5% over the past six months while the S&P 500 was up 6.8%.
- ❖Oct 26, 10:15 AMnewsvia finnhub
What You Need to Know Ahead of Bio-Techne’s Earnings Release
Bio-Techne will report its Q1 earnings soon, and analysts see single-digit earnings growth.
- ❖Oct 9, 10:43 AMnewsvia finnhub
1 Unpopular Stock That Should Get More Attention and 2 We Question
Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.
- ❖Oct 9, 7:02 AMnewsvia finnhub
Bio-Techne opens GMP small molecule facility in Bristol, UK
The purpose-built site is fully operational and produces materials to support developers working on cell therapies globally.
- ?Oct 8, 6:21 PMdecisionconsidered
Agent 20 — SIR Price/Volume — skip
[no_pattern] The 20-day PV path traces a remarkably tight, range-bound cluster between roughly $72.12 (2026-09-11) and $72.61 (2026-09-25), a span of less than 50 cents, with volume oscillating mostly between 1.9M and 5.0M — unremarkable relative to the 3.2M ADV until today. Today's bar (2026-10-08) does print an elevated volume of 5.4M (z-score 2.81), but the price response is a fractional -0.11% decline to $72.45, well inside the established cluster rather than breaking above it — the volume surge is not paired with a directional price escape. While there is mild up-day volume dominance in the early portion of the path (e.g., 2026-09-17 at 3.8M and 2026-09-21 at 4.7M on up days), the latter half of the path (2026-09-28 through today) shows a drift of down days with mixed-to-expanding volume, offsetting any accumulation read. Risks: A sustained close below $72.12 (the 20-day path low) on volume above 4.0M would confirm distribution and invalidate any residual accumulation thesis; conversely, a confirmed close above $72.61 on volume ≥ 5.0M would reopen the cluster_break_up case. Additionally, the macro backdrop of mortgage rates at 7.4% (3.8σ above trend) is sector-neutral for Health Care directly but signals broad risk-off pressure that could suppress any breakout attempt.
- ❖Oct 8, 8:00 AMnewsvia finnhub
Bio-Techne Expands Global GMP Manufacturing Network with New Bristol Facility to Advance Scalable Cell Therapy Development
Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents and diagnostic products, today announced the opening of a new manufacturing facility for Good Manufacturing Practice (GMP) grade small molecules in Bristol, United Kingdom, further expanding the company's global capabilities to support the rapidly growing cell therapy market. The investment reflects Bio-Techne's commitment to helping therapy developers address one of the industry's most pressing challenges:
- ❖Oct 8, 4:09 AMnewsvia finnhub
Bio-Techne Opens New Bristol Facility
Investment strengthens Bio-Techne's global GMP manufacturing infrastructure for cell therapy applicationsNew Bristol facility expands GMP small molecule production capacity and complements recent investments in
- ❖Oct 1, 7:01 AMnewsvia finnhub
Insider Activity Update: John L Higgins Executes Options Exercise, Resulting In $751K At Bio-Techne
On September 30, it was revealed in an SEC filing that John L Higgins, Director at Bio-Techne (NASDAQ:TECH) executed a significant exercise of company stock options. What Happened: A Form 4 filing with the U.S.
- ▣Sep 30, 8:00 PMjournalrotation
Agent 17 — 52-Week High Momentum closed long 67 @ $72.40 (+$6.03)
52-Week High monthly rebalance. Position retained in target set; re-entered at equal weight.
- ▢Sep 30, 8:00 PMjournal
Agent 17 — 52-Week High Momentum opened long 64 @ $72.40
- ❖Sep 30, 10:40 AMnewsvia finnhub
INCY or TECH: Which Is the Better Value Stock Right Now?
INCY vs. TECH: Which Stock Is the Better Value Option?
- ❖Sep 28, 9:42 AMnewsvia finnhub
2 Cash-Producing Stocks Worth Investigating and 1 We Brush Off
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
- ❖Sep 25, 11:57 PMnewsvia finnhub
Bio-Techne (TECH) Shareholders Approve the Merck KGaA Takeover and Reject the Pay Package
Bio-Techne Corporation (NASDAQ:TECH) shareholders voted on September 23 to approve the company’s acquisition by Merck KGaA of Darmstadt, Germany. The German group is paying $73 a share in cash, valuing the business at about $11.3 billion including debt. They also voted down the executive compensation proposal attached to the deal, which is an unusual pairing. […]
- ❖Sep 25, 7:00 AMnewsvia finnhub
Robert V Baumgartner Exercises Options, Realizes $754K
Robert V Baumgartner, Board Member at Bio-Techne (NASDAQ:TECH), reported a large exercise of company stock options on September 24, according to a new SEC filing. What Happened: In an insider options exercise disclosed
- ❖Sep 24, 4:47 AMnewsvia finnhub
Is Bio-Techne Stock Outperforming the Nasdaq?
Bio-Techne has outperformed the Nasdaq over the past year, but analysts are cautious about the stock’s prospects.
- ❖Sep 23, 9:41 AMnewsvia finnhub
3 Reasons to Sell TECH and 1 Stock to Buy Instead
Bio-Techne has had an impressive run over the past six months as its shares have beaten the S&P 500 by 21.5%. The stock now trades at $72.56, marking a 39.5% gain. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.
- ❖Sep 23, 9:20 AMnewsvia finnhub
Bio-Techne Shareholders Approve Acquisition by Merck KGaA, Darmstadt, Germany
Bio-Techne Corporation (NASDAQ: TECH) ("Bio-Techne"), a global provider of life science tools, reagents and diagnostic products, announced that Bio-Techne shareholders voted to approve and adopt the definitive agreement under which Merck KGaA, Darmstadt, Germany proposes to acquire Bio-Techne (the "Merger Agreement") at a Special Meeting of Shareholders held today.
- ❖Sep 23, 5:22 AMnewsvia finnhub
Bio-Techne Receives Shareholders' Approval For Proposed Acquisition By Merck KGaA
Bio-Techne Corporation (NASDAQ:TECH) ("Bio-Techne"), a global provider of life science tools, reagents and diagnostic products, announced that Bio-Techne shareholders voted to approve and adopt the definitive
- ❖Sep 22, 9:00 AMnewsvia finnhub
Bio-Techne Opens New Customer Experience Center in Düsseldorf to Accelerate Scientific Discovery and Customer Collaboration
Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents and diagnostic products, today announced the opening of its new Customer Experience Center in Düsseldorf, Germany, a flagship facility designed to bring European customers closer to Bio-Techne's latest innovations and scientific expertise.
- ❖Sep 22, 9:00 AMnewsvia finnhub
Bio-Techne Opens New Customer Experience Center in Düsseldorf to Accelerate Scientific Discovery and Customer Collaboration
Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents and diagnostic products, today announced the opening of its new Customer Experience Center in Düsseldorf, Germany, a flagship facility designed to bring European customers closer to Bio-Techne's latest innovations and scientific expertise.
- ❖Sep 15, 12:30 AMnewsvia finnhub
Bio Techne (TECH) And The Valuation Case Behind Its Recent Rebound
Bio-Techne (TECH) has drawn fresh attention after recent trading left the share price at $72.27, with performance over the past month roughly flat and the past 3 months showing a strong double digit gain. Recent trading tells a mixed story for Bio-Techne. The share price return of 29% over the past 90 days sits alongside a 1-year total shareholder return of 41%, while the 5-year total shareholder return shows a decline of 44%. This hints that momentum has only recently improved following a...
- ❖Sep 11, 11:30 AMnewsvia finnhub
Why Is Techne (TECH) Down 0.1% Since Last Earnings Report?
Techne (TECH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- ❖Sep 8, 8:35 AMnewsvia finnhub
These S&P500 stocks are moving in today's pre-market session
Stay updated with the S&P500 stocks that are on the move in today's pre-market session.
- ❖Sep 1, 7:30 AMnewsvia finnhub
Bio-Techne Achieves Science Based Targets Validation and Reports Significant Progress Toward Climate Goals
Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents and diagnostic products, today announced significant progress toward its climate and sustainability objectives, including validation of its greenhouse gas reduction targets by the Science Based Targets initiative (SBTi) and substantial reductions in operational emissions during fiscal year 2026.
- ❖Sep 1, 2:36 AMnewsvia finnhub
Bio-Techne Announces SBTi Validation Of 70% Scope 1 & 2 Emissions Reduction Target By FY2031 And Supplier Engagement Commitment, Reporting Significant Operational Emissions Cuts In FY2026
Fiscal 2026 highlights:Science Based Targets initiative validates Bio-Techne's Scope 1, 2 and 3 greenhouse gas reduction targetsMarket-based Scope 1 and 2 emissions reduced 49% year-over-yearMore than half of the
- ▣Aug 31, 8:00 PMjournalrotation
Agent 17 — 52-Week High Momentum closed long 68 @ $72.31 (+$11.56)
52-Week High monthly rebalance. Position retained in target set; re-entered at equal weight.
- ▢Aug 31, 8:00 PMjournal
Agent 17 — 52-Week High Momentum opened long 67 @ $72.31
- ❖Aug 31, 6:08 PMnewsvia finnhub
Winners And Losers Of Q2: Bio-Techne (NASDAQ:TECH) Vs The Rest Of The Research Tools & Consumables Stocks
Wrapping up Q2 earnings, we look at the numbers and key takeaways for the research tools & consumables stocks, including Bio-Techne (NASDAQ:TECH) and its peers.
- ❖Aug 26, 5:53 PMnewsvia finnhub
Tracking Ruane, Cunniff, & Goldfarb's Portfolio - Q2 2026 Update
Ruane, Cunniff & Goldfarb Q2 2026 13F: key holdings, new buys & trims, and Sequoia Fund vs S&P 500. Read here for a detailed investment analysis.
- ▣Aug 24, 8:00 PMjournaltime_stop
Agent 8 — Dip Buyer (Peer-Aware) closed long 16 @ $72.34 (+$365.09)
Time stop: held 90 ≥ 90 days
- ❖Aug 7, 4:14 PMnewsvia finnhub
Is Bio-Techne (TECH) Above Fair Value After A 44% Return?
Bio-Techne stock has delivered a strong 44.2% return over the past year, yet both its Discounted Cash Flow (DCF) intrinsic value estimate and market multiples currently point to the shares trading at a premium rather than as an obvious bargain. Over the last 12 months, Bio-Techne has returned 44.2%, which puts a clear spotlight on whether recent gains already reflect much of the good news in the price. Expectations around Bio-Techne's ability to grow revenue and sustain healthy cash flows...
- ❖Aug 6, 11:40 AMnewsvia finnhub
JAZZ vs. TECH: Which Stock Is the Better Value Option?
JAZZ vs. TECH: Which Stock Is the Better Value Option?
- ❖Aug 6, 9:57 AMnewsvia finnhub
Investors’ Confidence in Bio-Techne Corp. (TECH) Strengthens as Headwind Eases
Conestoga Capital Advisors, an asset management company, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The letter reports a positive market shift towards Small Caps, with the Russell 2000 Index achieving its best first half since 1991 and the Russell 2000 Growth Index up 25.7% in Q2, fueled by AI […]
- ❖Aug 4, 5:49 AMnewsvia finnhub
2 S&P 500 Stocks to Keep an Eye On and 1 We Turn Down
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.
- ❖Aug 4, 1:01 AMnewsvia finnhub
1 Healthcare Stock Worth Your Attention and 2 We Question
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have not only realized strong financial performance but also propelled the broader industry’s returns as healthcare stocks have gained 16.6% over the past six months while the S&P 500 was up 7.1%.
- ▢Aug 2, 8:00 PMjournal
Agent 17 — 52-Week High Momentum opened long 68 @ $72.14
- ❖Jul 31, 5:49 AMnewsvia finnhub
Madison Mid Cap Fund Q2 2026 Portfolio Activity
The top five contributors for the quarter were MKS, Amphenol, Arista Networks, Bio-Techne, and Waters.
- ❖Jul 31, 4:38 AMnewsvia finnhub
Conestoga SMid Cap Composite Q2 2026 Portfolio Review
We were attracted to Knowles' accelerating organic growth, expanding margins, and exposure to several attractive long-term secular trends.
- ❖Jul 29, 9:05 AMnewsvia finnhub
Bio-Techne's Q4 Earnings on Deck: What's in Store for the Stock?
TECH heads into fiscal fourth-quarter earnings with revenues expected to remain flat, EPS projected to decline, and its $11.3 billion acquisition deal in focus.
- ▣Jul 23, 8:00 PMjournalexpired_settlement
options_momentum closed long 70 @ $12.60 (+$650.92)
SETTLED 2026-09-17 (mig 257): contract expired 2026-07-24 while the agent was disabled; settled at intrinsic 12.6000 from underlying close 71.6 (Massive, unadjusted). Was carried at stale 7/2 mark 12.1555.
- ❖Jul 20, 8:12 AMnewsvia finnhub
What to Expect From Bio-Techne's Next Quarterly Earnings Report
Bio-Techne is scheduled to post its fourth-quarter results soon, and analysts project a single-digit earnings decline.
- ❖Jul 16, 3:13 PMnewsvia finnhub
Q1 Earnings Outperformers: Bio-Techne (NASDAQ:TECH) And The Rest Of The Research Tools & Consumables Stocks
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Bio-Techne (NASDAQ:TECH) and the best and worst performers in the research tools & consumables industry.
- ❖Jul 13, 8:41 AMnewsvia finnhub
Revvity: Overvalued On Sentiment
Revvity, Inc. trades near 52-week highs, buoyed by sector M&A momentum but faces fundamental headwinds. Learn more about RVTY stock now.
- ❖Jul 10, 5:26 AMnewsvia finnhub
Qiagen M&A Fever Builds: KKR, EQT, Advent Explore Possible Takeover
Private equity giants circle Qiagen (QGEN) with potential bids of $50/share. Get the details on the molecular diagnostics buyout.
- ▣Jun 25, 8:00 PMjournalmanual
Agent 8 — Dip Buyer (Peer-Aware) closed long 15 @ $70.22 (+$310.48)
Staged exit (1/2.0): close $70.70 ≥ target $62.47. Selling 15/31 sh, trailing remainder.
- !Jun 25, 1:35 PMsignal
options_momentum — insufficient_capital
- ▣Jun 24, 8:00 PMjournaltarget
options_momentum closed long 30 @ $12.08 (+$263.30)
De-risk: premium $12.08 ≥ 2.0× entry $3.30. Selling 30/100 contracts; trailing the remainder.
- ?Jun 24, 6:05 PMdecisionconsidered
Agent 20 — SIR Price/Volume — buy
[not executed — reserve_floor_or_cash] [accumulation] Over the 20-day path, TECH has traced a persistent up-and-right drift: the stock climbed from $48.09 (2026-05-27, 2.2M) to $58.86 (2026-06-24, 3.8M), a ~22% gain, with up-day volume consistently dominating down-day volume. Specifically, the four largest volume sessions — 2026-06-04 (4.2M, +4.58%), 2026-06-08 (4.4M, +1.27%), 2026-06-09 (3.6M, +3.34%), and today 2026-06-24 (3.8M, +4.62%) — were all UP days, while down-day volume was consistently muted (e.g., 2026-06-10 at 2.6M, 2026-06-16 at 1.5M, 2026-06-22 at 2.0M). Today's close at $58.86 on 3.8M (z-score +1.30 vs. the 20-day mean of 2.8M) marks a new path high on expanding volume, consistent with institutional accumulation rather than a single-bar anomaly. The macro tailwind — 10Y inflation expectations 2.0σ below trend (2.21 on 2026-06-23) — further supports long-duration Health Care names like TECH, as compressed real yields typically benefit growth-oriented healthcare multiples. Risks: A reversal back below the $56–$54 support band on elevated volume (>3.5M) would signal distribution overwhelming the accumulation read and invalidate the setup. Additionally, if 10Y inflation expectations snap back sharply toward trend, the macro tailwind for long-duration Health Care names would dissipate, removing a key supporting factor.
- ?Jun 24, 10:25 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
TECH is up 6.81% intraday with no headline catalyst visible, suggesting this is flow-driven — likely a catalyst known to institutional participants (earnings revision, upgrade, or sector rotation) that preceded public headlines. A move of this magnitude represents genuine conviction from size players. However, several factors temper the continuation thesis: (1) With 320 minutes remaining (over 5 hours), there is ample time but also ample risk of mean reversion after a sharp gap/spike — large moves without news often see profit-taking as the session matures. (2) The macro context shows 10Y inflation breakevens (T10YIE) printing 2.0 sigma below trend, which is bullish for long-duration and growth-sensitive sectors like tech — this is a modest tailwind supporting the direction. (3) No reversals or fade patterns are noted; the move appears sustained from current data. (4) Absence of news does not disqualify, per framework. Overall, the balance of evidence supports a modest continuation bias — the macro backdrop is supportive, no fade signal is present, and the move size indicates real institutional flow — but the lack of a known catalyst and the risk of intraday exhaustion after a near-7% move cap confidence at a moderate level.
- !Jun 24, 10:25 AMsignalseverity 0.07
Agent 7 — Day Trader — day_trade_skipped
TECH is up 6.81% intraday with no headline catalyst visible, suggesting this is flow-driven — likely a catalyst known to institutional participants (earnings revision, upgrade, or sector rotation) that preceded public headlines. A move of this magnitude represents genuine conviction from size players. However, several factors temper the continuation thesis: (1) With 320 minutes remaining (over 5 hours), there is ample time but also ample risk of mean reversion after a sharp gap/spike — large moves without news often see profit-taking as the session matures. (2) The macro context shows 10Y inflation breakevens (T10YIE) printing 2.0 sigma below trend, which is bullish for long-duration and growth-sensitive sectors like tech — this is a modest tailwind supporting the direction. (3) No reversals or fade patterns are noted; the move appears sustained from current data. (4) Absence of news does not disqualify, per framework. Overall, the balance of evidence supports a modest continuation bias — the macro backdrop is supportive, no fade signal is present, and the move size indicates real institutional flow — but the lack of a known catalyst and the risk of intraday exhaustion after a near-7% move cap confidence at a moderate level.
- ✓Jun 24, 9:51 AMdecisionacted
options_momentum — decide: buy
CALL on TECH — 5-day return 5.30% with close above 20-day MA ($53.54). IV 47.4%. Sized 1 contract(s) at $3.30 premium.
- ▢Jun 23, 8:00 PMjournal
options_momentum opened long 30 @ $3.30
- ▢Jun 23, 8:00 PMjournal
options_momentum opened long 70 @ $3.30
- ?Jun 23, 9:36 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
TECH is up 1.65% today, a modest but real move suggesting genuine buying interest. There are no headlines to explain or catalyze the move, which is common and not disqualifying. The macro context is mildly supportive: T10YIE at 1.7σ below its 24-month trend implies compressed inflation expectations, which is favorable for long-duration sensitive sectors — and tech/growth equities are classically long-duration assets that benefit from lower real/nominal rates. With 369 minutes remaining (well over 6 hours, suggesting this is early-to-mid session), there is ample time for continuation. The move at 1.65% is below the 2-5% 'high conviction' threshold, so it doesn't carry strong momentum signal on its own. No reversal pattern is evident, and no fade cues are present. No volume data is available to confirm or deny institutional participation. On balance, the macro tailwind (low inflation expectations favoring long-duration growth) combined with time remaining and absence of fade signals tips this modestly toward continuation. Probability sits at the lower end of the ordinary momentum band — enough to take the trade given bounded risk parameters.
- !Jun 23, 9:36 AMsignalseverity 0.02
Agent 7 — Day Trader — day_trade_skipped
TECH is up 1.65% today, a modest but real move suggesting genuine buying interest. There are no headlines to explain or catalyze the move, which is common and not disqualifying. The macro context is mildly supportive: T10YIE at 1.7σ below its 24-month trend implies compressed inflation expectations, which is favorable for long-duration sensitive sectors — and tech/growth equities are classically long-duration assets that benefit from lower real/nominal rates. With 369 minutes remaining (well over 6 hours, suggesting this is early-to-mid session), there is ample time for continuation. The move at 1.65% is below the 2-5% 'high conviction' threshold, so it doesn't carry strong momentum signal on its own. No reversal pattern is evident, and no fade cues are present. No volume data is available to confirm or deny institutional participation. On balance, the macro tailwind (low inflation expectations favoring long-duration growth) combined with time remaining and absence of fade signals tips this modestly toward continuation. Probability sits at the lower end of the ordinary momentum band — enough to take the trade given bounded risk parameters.
- ?Jun 22, 11:00 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
TECH is down 3.19% intraday with no attributable headline, suggesting this is flow/positioning-driven rather than news-driven. A move of this magnitude reflects real selling conviction. However, several factors temper the continuation case: (1) With 285 minutes remaining (nearly a full session still ahead), there is ample time but also ample time for mean reversion — this is not a late-day momentum lock-in scenario. (2) The macro context (5Y inflation breakevens 1.5σ below trend) is modestly deflationary, which is mixed for equities broadly and does not provide a clear sector-specific tailwind for continuation in TECH. (3) No news to anchor further selling means the move could be exhausting — large drops without catalysts often see afternoon recovery as dip buyers step in. (4) No volume data is provided to confirm whether selling pressure is sustained. Balancing the meaningful downside momentum (which itself is evidence of real flow) against the lack of a narrative anchor, ample time for reversal, and a mildly ambiguous macro backdrop, I assign a modest continuation probability just above the threshold. The bounded risk profile (-1.5% stop, +3% target) justifies taking the trade at this slim edge.
- !Jun 22, 11:00 AMsignalseverity -0.03
Agent 7 — Day Trader — day_trade_skipped
TECH is down 3.19% intraday with no attributable headline, suggesting this is flow/positioning-driven rather than news-driven. A move of this magnitude reflects real selling conviction. However, several factors temper the continuation case: (1) With 285 minutes remaining (nearly a full session still ahead), there is ample time but also ample time for mean reversion — this is not a late-day momentum lock-in scenario. (2) The macro context (5Y inflation breakevens 1.5σ below trend) is modestly deflationary, which is mixed for equities broadly and does not provide a clear sector-specific tailwind for continuation in TECH. (3) No news to anchor further selling means the move could be exhausting — large drops without catalysts often see afternoon recovery as dip buyers step in. (4) No volume data is provided to confirm whether selling pressure is sustained. Balancing the meaningful downside momentum (which itself is evidence of real flow) against the lack of a narrative anchor, ample time for reversal, and a mildly ambiguous macro backdrop, I assign a modest continuation probability just above the threshold. The bounded risk profile (-1.5% stop, +3% target) justifies taking the trade at this slim edge.
- ▣Jun 21, 8:00 PMjournalstop
options_momentum closed long 100 @ $2.55 (-$29.23)
Stop: premium $2.55 ≤ trailing floor $2.62 (peak $3.49 × 0.75)
- ?Jun 18, 2:51 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
TECH is up 4.53% intraday with no attributable headline, suggesting institutional flow or sector rotation rather than a news-driven spike. A move of this magnitude reflects real conviction and is not easily dismissed. However, several factors temper continuation confidence: (1) Only 55 minutes remain until the forced 3:45 PM ET close, which significantly compresses the runway for further upside and increases the probability of profit-taking into the close. (2) The macro backdrop shows T10Y2Y at 3.5σ below its 24-month trend — a flat/inverted curve environment is not directly bearish for tech, but the anomalous rate signal introduces cross-asset uncertainty that could weigh on risk appetite late session. (3) No news catalyst means the move could be momentum-driven accumulation OR a large block trade that is now complete, leaving less follow-through fuel. (4) At 4.53% up, the stock is already near or past the system's +3% profit target threshold, meaning the asymmetric reward window may be partially consumed. Balancing the real but waning momentum signal against limited time and a mildly unfavorable macro backdrop, I assign a modest continuation probability just above the action threshold.
- !Jun 18, 2:51 PMsignalseverity 0.05
Agent 7 — Day Trader — day_trade_skipped
TECH is up 4.53% intraday with no attributable headline, suggesting institutional flow or sector rotation rather than a news-driven spike. A move of this magnitude reflects real conviction and is not easily dismissed. However, several factors temper continuation confidence: (1) Only 55 minutes remain until the forced 3:45 PM ET close, which significantly compresses the runway for further upside and increases the probability of profit-taking into the close. (2) The macro backdrop shows T10Y2Y at 3.5σ below its 24-month trend — a flat/inverted curve environment is not directly bearish for tech, but the anomalous rate signal introduces cross-asset uncertainty that could weigh on risk appetite late session. (3) No news catalyst means the move could be momentum-driven accumulation OR a large block trade that is now complete, leaving less follow-through fuel. (4) At 4.53% up, the stock is already near or past the system's +3% profit target threshold, meaning the asymmetric reward window may be partially consumed. Balancing the real but waning momentum signal against limited time and a mildly unfavorable macro backdrop, I assign a modest continuation probability just above the action threshold.
- ✓Jun 18, 10:20 AMdecisionacted
options_momentum — decide: buy
CALL on TECH — 5-day return 5.12% with close above 20-day MA ($52.12). IV 39.8%. Sized 1 contract(s) at $2.85 premium.
- ▢Jun 17, 8:00 PMjournal
options_momentum opened long 100 @ $2.85
- ▣Jun 16, 8:00 PMjournalstop
options_momentum closed long 100 @ $1.85 (-$94.67)
Stop: premium $1.85 ≤ trailing floor $2.10 (peak $2.80 × 0.75)
- ?Jun 15, 9:56 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
TECH is up 4.22% intraday — a meaningful move reflecting real buying flow. The only headline is a cautious initiation from Piper Sandler noting patience on sector growth drivers, which is mildly negative sentiment but does not explain the move and does not constitute a catalyst that would sustain further buying. The macro backdrop (T10Y2Y at 2.2σ below trend, slight bear-flattening environment) is marginally unfavorable for growth/tech-adjacent names but TECH (Bio-Techne) is a life sciences tools company with some defensive characteristics, so macro drag is limited. With 349 minutes remaining there is ample time for continuation, which is a positive factor. However, the absence of a clear catalyst driving the move introduces uncertainty about whether the buying is exhausted or still has legs. No reversal signal is evident from the data provided. On balance, the move has momentum behind it and time remains, but the lack of a clear driver and the mildly cautious sector headline warrant only modest confidence. Assigning a slight lean toward continuation consistent with the system's borderline-resolve rule.
- !Jun 15, 9:56 AMsignalseverity 0.04
Agent 7 — Day Trader — day_trade_skipped
TECH is up 4.22% intraday — a meaningful move reflecting real buying flow. The only headline is a cautious initiation from Piper Sandler noting patience on sector growth drivers, which is mildly negative sentiment but does not explain the move and does not constitute a catalyst that would sustain further buying. The macro backdrop (T10Y2Y at 2.2σ below trend, slight bear-flattening environment) is marginally unfavorable for growth/tech-adjacent names but TECH (Bio-Techne) is a life sciences tools company with some defensive characteristics, so macro drag is limited. With 349 minutes remaining there is ample time for continuation, which is a positive factor. However, the absence of a clear catalyst driving the move introduces uncertainty about whether the buying is exhausted or still has legs. No reversal signal is evident from the data provided. On balance, the move has momentum behind it and time remains, but the lack of a clear driver and the mildly cautious sector headline warrant only modest confidence. Assigning a slight lean toward continuation consistent with the system's borderline-resolve rule.
- ✓Jun 15, 9:47 AMdecisionacted
options_momentum — decide: buy
CALL on TECH — 5-day return 6.89% with close above 20-day MA ($50.56). IV 38.4%. Sized 1 contract(s) at $2.80 premium.
- ▢Jun 14, 8:00 PMjournal
options_momentum opened long 100 @ $2.80
- ▣Jun 10, 8:00 PMjournalstop
options_momentum closed long 100 @ $4.33 (-$86.30)
Stop: premium $4.33 ≤ trailing floor $4.39 (peak $5.86 × 0.75)
- ?Jun 9, 9:55 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
TECH is up 4.08% intraday with no attributable headline, suggesting this is flow-driven — likely institutional or systematic buying. A move of this magnitude represents real conviction and should not be dismissed. However, there are several moderating factors: (1) No news catalyst means the move could be vulnerable to profit-taking as the session progresses, especially after a 4%+ run. (2) The macro context shows T10Y2Y at 0.41, 2.0σ below its 24-month trend — a flattening/near-inverted yield curve typically pressures growth/tech names as it signals economic slowdown concerns. (3) 350 minutes remaining is substantial time, which cuts both ways — enough runway for continuation but also enough time for a fade. (4) Absence of headlines removes a potential re-acceleration catalyst. On balance, the raw momentum and size of the move slightly favor continuation into the close, but the yield curve backdrop is a meaningful headwind for a tech name specifically. Probability sits modestly above 0.5 — a weak continuation signal sufficient to take the trade given the bounded risk structure, but not a high-conviction setup.
- !Jun 9, 9:55 AMsignalseverity 0.04
Agent 7 — Day Trader — day_trade_skipped
TECH is up 4.08% intraday with no attributable headline, suggesting this is flow-driven — likely institutional or systematic buying. A move of this magnitude represents real conviction and should not be dismissed. However, there are several moderating factors: (1) No news catalyst means the move could be vulnerable to profit-taking as the session progresses, especially after a 4%+ run. (2) The macro context shows T10Y2Y at 0.41, 2.0σ below its 24-month trend — a flattening/near-inverted yield curve typically pressures growth/tech names as it signals economic slowdown concerns. (3) 350 minutes remaining is substantial time, which cuts both ways — enough runway for continuation but also enough time for a fade. (4) Absence of headlines removes a potential re-acceleration catalyst. On balance, the raw momentum and size of the move slightly favor continuation into the close, but the yield curve backdrop is a meaningful headwind for a tech name specifically. Probability sits modestly above 0.5 — a weak continuation signal sufficient to take the trade given the bounded risk structure, but not a high-conviction setup.
- ?Jun 5, 2:55 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
TECH is down 2.91% intraday with no headline catalyst, suggesting this is flow/positioning driven rather than a news event that could reverse on clarification. The macro context shows T10Y2Y at 1.9σ below its 24-month trend — a flattening/near-inverted curve that favors defensives and pressures growth/tech names, providing a mild tailwind for continued selling pressure. With only 50 minutes remaining, there is limited runway for continuation, which caps the probability. No reversal pattern is evident (no mention of fade off lows or recovery attempt), and the move has been meaningful enough to suggest real conviction from sellers. However, the time constraint and absence of any supporting volume data or news anchor keep this in the modest continuation range rather than a high-conviction setup. Net assessment: slight lean toward continuation of the downside move into the close, but marginal.
- !Jun 5, 2:55 PMsignalseverity -0.03
Agent 7 — Day Trader — day_trade_skipped
TECH is down 2.91% intraday with no headline catalyst, suggesting this is flow/positioning driven rather than a news event that could reverse on clarification. The macro context shows T10Y2Y at 1.9σ below its 24-month trend — a flattening/near-inverted curve that favors defensives and pressures growth/tech names, providing a mild tailwind for continued selling pressure. With only 50 minutes remaining, there is limited runway for continuation, which caps the probability. No reversal pattern is evident (no mention of fade off lows or recovery attempt), and the move has been meaningful enough to suggest real conviction from sellers. However, the time constraint and absence of any supporting volume data or news anchor keep this in the modest continuation range rather than a high-conviction setup. Net assessment: slight lean toward continuation of the downside move into the close, but marginal.
- ✓Jun 4, 11:15 AMdecisionacted
Agent 7 — Day Trader — decide: buy
TECH is up 3.72% intraday, which represents meaningful real-money flow and conviction. The headline (Bio-Techne/Refeyn partnership on bispecific antibody characterization) is modestly positive for the life sciences tools space but not a blockbuster catalyst — it reads more as a business update than a transformative event. With 270 minutes remaining (roughly 4.5 hours), there is ample time for the move to extend or at minimum hold into the close. The macro backdrop (T10Y2Y at 0.41, 2.1σ below trend) is modestly unfavorable for risk-on names if the market interprets flattening as a growth concern, but TECH/life sciences tools are not acutely rate-sensitive and do not map cleanly to the 'Banks negatively, Defensives' reactive sectors noted. No reversal signal or fade pattern is indicated. The move is in the meaningful 3-5% range suggesting institutional flow rather than retail noise. No strong reason to fade — assigning modest continuation probability above 0.5 reflecting genuine momentum without exceptional conviction.
- ✓Jun 4, 10:46 AMdecisionacted
Agent 8 — Dip Buyer (Peer-Aware) — pyramid
Pyramid add-on fired at +10.03% unrealized. Added 10 sh @ $52.78 ($527.80). Position now 31 sh @ weighted avg $49.52.
- ?Jun 4, 9:01 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
TECH is up 2.17% today with 405 minutes remaining (well over 6 hours, suggesting this is early-to-mid session), giving ample time for continuation. The headline references a product/partnership development (Bio-Techne/Refeyn bispecific antibody characterization) that is modestly positive for the life-sciences tools space — not a blockbuster catalyst, but directionally supportive. The macro context (T10Y2Y at 0.41, 2.1σ below 24-month trend) reflects a flattening/mild inversion environment that is somewhat unfavorable for cyclicals and banks but is broadly neutral-to-mildly supportive for growth/biotech names as it implies rate expectations are softening. No reversal signal is evident — the move is a clean up trend with no mention of fade from highs. Absent evidence of thin volume or a reversal pattern, the default lean per the framework is continuation. The 2.17% move represents real institutional flow. Probability stays modest rather than elevated because the news catalyst is incremental rather than transformational, and the macro backdrop is not strongly tailwind. Assigning 0.54 — a mild continuation lean, sufficient to trigger per the system rules, but not a high-conviction setup.
- !Jun 4, 9:01 AMsignalseverity 0.02
Agent 7 — Day Trader — day_trade_skipped
TECH is up 2.17% today with 405 minutes remaining (well over 6 hours, suggesting this is early-to-mid session), giving ample time for continuation. The headline references a product/partnership development (Bio-Techne/Refeyn bispecific antibody characterization) that is modestly positive for the life-sciences tools space — not a blockbuster catalyst, but directionally supportive. The macro context (T10Y2Y at 0.41, 2.1σ below 24-month trend) reflects a flattening/mild inversion environment that is somewhat unfavorable for cyclicals and banks but is broadly neutral-to-mildly supportive for growth/biotech names as it implies rate expectations are softening. No reversal signal is evident — the move is a clean up trend with no mention of fade from highs. Absent evidence of thin volume or a reversal pattern, the default lean per the framework is continuation. The 2.17% move represents real institutional flow. Probability stays modest rather than elevated because the news catalyst is incremental rather than transformational, and the macro backdrop is not strongly tailwind. Assigning 0.54 — a mild continuation lean, sufficient to trigger per the system rules, but not a high-conviction setup.
- ?Jun 4, 7:02 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $43.66 cash available; close=$50.85.
- !Jun 4, 7:02 AMsignal
Agent 5 — Dip Buyer (Evolving) — insufficient_capital
Wanted to buy but only $3.84 cash available; close=$50.85.
- ▢Jun 3, 8:00 PMjournal
Agent 7 — Day Trader opened long 28 @ $52.74
- ▣Jun 3, 8:00 PMjournalstop
Agent 7 — Day Trader closed long 28 @ $51.89 (-$23.94)
Long stop: close $51.88 ≤ stop $51.95
- ?Jun 3, 6:05 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $3.84 cash available; close=$50.85.
- !Jun 3, 6:05 PMsignal
Agent 5 — Dip Buyer (Evolving) — insufficient_capital
Wanted to buy but only $1.04 cash available; close=$50.79.
- ?Jun 3, 10:37 AMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
There are no news headlines or SEC filings in the 30-day window to explain the 18.7% drop, suggesting it may be driven by macro rotation or sector-level selling pressure rather than company-specific deterioration. The T10Y3M spread is elevated at 0.76 (1.6σ above trend), indicating a steepening yield curve environment that tends to pressure growth/tech names and favor cyclicals and banks, which could explain continued headwinds for TECH. With no fundamental evidence to anchor a recovery thesis and an unfavorable macro backdrop for the sector, confidence in a rebound to the 30-day high within 90 days is limited.
- !Jun 3, 10:37 AMsignalseverity 0.18
Agent 4 — Dip Buyer (Frozen) — dip_skipped
There are no news headlines or SEC filings in the 30-day window to explain the 18.7% drop, suggesting it may be driven by macro rotation or sector-level selling pressure rather than company-specific deterioration. The T10Y3M spread is elevated at 0.76 (1.6σ above trend), indicating a steepening yield curve environment that tends to pressure growth/tech names and favor cyclicals and banks, which could explain continued headwinds for TECH. With no fundamental evidence to anchor a recovery thesis and an unfavorable macro backdrop for the sector, confidence in a rebound to the 30-day high within 90 days is limited.
- ?Jun 3, 10:36 AMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
There are no news headlines or SEC filings in the 30-day window to explain the 18.7% drop, suggesting it may be driven by macro rotation or sector-level selling pressure rather than company-specific deterioration. The T10Y3M spread is elevated at 0.76 (1.6σ above trend), indicating a steepening yield curve environment that tends to pressure growth/tech names and favor cyclicals and banks, which could explain continued headwinds for TECH. With no fundamental evidence to anchor a recovery thesis and an unfavorable macro backdrop for the sector, confidence in a rebound to the 30-day high within 90 days is limited.
- ?Jun 3, 9:06 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
TECH is down 2.01% intraday with no attributable headline, suggesting institutional selling or sector rotation rather than a news-driven spike that might quickly reverse. The macro context shows T10Y2Y at 2.0σ below its 24-month trend, indicating a flattening/slightly inverted curve environment that tends to pressure growth/tech names as risk appetite softens and discount rates remain a concern. With 400 minutes remaining (well over 6 hours, which far exceeds the trading day — interpreting this as likely ~75-90 minutes to the 3:45 ET cutoff based on typical session timing), there is meaningful time for the move to extend. No reversal signals are explicitly present, and the absence of news does not disqualify momentum. However, the move is modest at ~2% and without confirming volume data or a clear catalyst, conviction is limited. Rating continuation probability at 0.52 — slight lean toward continuation given macro headwinds for tech and sustained selling pressure, but not a high-conviction setup.
- !Jun 3, 9:06 AMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
TECH is down 2.01% intraday with no attributable headline, suggesting institutional selling or sector rotation rather than a news-driven spike that might quickly reverse. The macro context shows T10Y2Y at 2.0σ below its 24-month trend, indicating a flattening/slightly inverted curve environment that tends to pressure growth/tech names as risk appetite softens and discount rates remain a concern. With 400 minutes remaining (well over 6 hours, which far exceeds the trading day — interpreting this as likely ~75-90 minutes to the 3:45 ET cutoff based on typical session timing), there is meaningful time for the move to extend. No reversal signals are explicitly present, and the absence of news does not disqualify momentum. However, the move is modest at ~2% and without confirming volume data or a clear catalyst, conviction is limited. Rating continuation probability at 0.52 — slight lean toward continuation given macro headwinds for tech and sustained selling pressure, but not a high-conviction setup.
- ✓Jun 3, 7:02 AMdecisionacted
Agent 5 — Dip Buyer (Evolving) — decide: buy
Wanted to buy but only $1.04 cash available; close=$50.79.
- ✓Jun 2, 6:04 PMdecisionacted
Agent 5 — Dip Buyer (Evolving) — decide: buy
Wanted to buy but only $1.04 cash available; close=$50.79.
- ?Jun 2, 3:30 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
With only 15 minutes remaining until the forced close, there is very little time for the move to extend meaningfully. The -1.81% decline is a moderate move but not extreme enough to signal a panic washout that typically runs further. The macro context (T10Y2Y at 2.0σ below trend, bear-flattening signal) is modestly negative for risk assets but TECH is not a bank or classic defensive sector — the macro signal is not a strong directional driver here. No headlines to confirm or deny a thesis. The critical factor is time: 15 minutes is insufficient runway for a continuation trade given the system's +3% profit target — even with tight stops, the expected value of initiating a short-side momentum trade in the final 15 minutes is negative when the move is sub-2% and there is no catalytic news or volume confirmation available. Late-session dynamics also introduce mean-reversion risk as institutional desks flatten positions into the close. Probability set below 0.5 primarily due to time constraint and absence of any continuation catalyst.
- !Jun 2, 3:30 PMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
With only 15 minutes remaining until the forced close, there is very little time for the move to extend meaningfully. The -1.81% decline is a moderate move but not extreme enough to signal a panic washout that typically runs further. The macro context (T10Y2Y at 2.0σ below trend, bear-flattening signal) is modestly negative for risk assets but TECH is not a bank or classic defensive sector — the macro signal is not a strong directional driver here. No headlines to confirm or deny a thesis. The critical factor is time: 15 minutes is insufficient runway for a continuation trade given the system's +3% profit target — even with tight stops, the expected value of initiating a short-side momentum trade in the final 15 minutes is negative when the move is sub-2% and there is no catalytic news or volume confirmation available. Late-session dynamics also introduce mean-reversion risk as institutional desks flatten positions into the close. Probability set below 0.5 primarily due to time constraint and absence of any continuation catalyst.
- ?Jun 2, 10:05 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
TECH is down 2.15% intraday with no headline catalyst, suggesting this is flow/macro driven rather than a news spike that could quickly reverse. The macro context is modestly negative for risk assets: T10Y2Y at 0.42 is 2.0σ below trend, indicating a flattening or slightly bear-flattening curve environment, which tends to pressure growth/tech names as discount rates concerns linger and risk appetite softens. With 340 minutes remaining there is ample time for continuation, so the time factor does not compress the probability. However, the absence of any news means we cannot confirm institutional conviction, and a -2.15% move without a catalyst carries some mean-reversion risk as intraday sellers may have exhausted near-term supply. Balancing the macro headwind and momentum signal against the lack of a news anchor and no volume data to confirm strength, this is a borderline continuation setup. Probability sits just above 0.5, favoring a modest continuation trade with tight stop discipline.
- !Jun 2, 10:05 AMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
TECH is down 2.15% intraday with no headline catalyst, suggesting this is flow/macro driven rather than a news spike that could quickly reverse. The macro context is modestly negative for risk assets: T10Y2Y at 0.42 is 2.0σ below trend, indicating a flattening or slightly bear-flattening curve environment, which tends to pressure growth/tech names as discount rates concerns linger and risk appetite softens. With 340 minutes remaining there is ample time for continuation, so the time factor does not compress the probability. However, the absence of any news means we cannot confirm institutional conviction, and a -2.15% move without a catalyst carries some mean-reversion risk as intraday sellers may have exhausted near-term supply. Balancing the macro headwind and momentum signal against the lack of a news anchor and no volume data to confirm strength, this is a borderline continuation setup. Probability sits just above 0.5, favoring a modest continuation trade with tight stop discipline.
- ?Jun 2, 7:01 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $1.04 cash available; close=$50.79.
- !Jun 2, 7:01 AMsignal
Agent 5 — Dip Buyer (Evolving) — insufficient_capital
Wanted to buy but only $2.27 cash available; close=$50.81.
- ?Jun 1, 6:03 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
There are no news headlines or SEC filings in the 30-day window to explain the 18.7% drop, suggesting it may be driven by macro rotation or sector-level selling pressure rather than company-specific deterioration. The T10Y3M spread is elevated at 0.76 (1.6σ above trend), indicating a steepening yield curve environment that tends to pressure growth/tech names and favor cyclicals and banks, which could explain continued headwinds for TECH. With no fundamental evidence to anchor a recovery thesis and an unfavorable macro backdrop for the sector, confidence in a rebound to the 30-day high within 90 days is limited.
- !Jun 1, 6:03 PMsignalseverity 0.19
Agent 4 — Dip Buyer (Frozen) — dip_skipped
There are no news headlines or SEC filings in the 30-day window to explain the 18.7% drop, suggesting it may be driven by macro rotation or sector-level selling pressure rather than company-specific deterioration. The T10Y3M spread is elevated at 0.76 (1.6σ above trend), indicating a steepening yield curve environment that tends to pressure growth/tech names and favor cyclicals and banks, which could explain continued headwinds for TECH. With no fundamental evidence to anchor a recovery thesis and an unfavorable macro backdrop for the sector, confidence in a rebound to the 30-day high within 90 days is limited.
- ?Jun 1, 6:03 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $2.27 cash available; close=$50.81.
- !Jun 1, 6:03 PMsignal
Agent 5 — Dip Buyer (Evolving) — insufficient_capital
Net signal score: +3. TECH (Bio-Techne) is down 17.3% from its 30-day high — a drop magnitude >=15% without any identified fundamental cause (+1 mean-reversion candidate). No earnings are visible within the 90-day window (+1 clean runway). The Health Care sector is underperforming the market (30d rel-strength rank 3/11 but down 5.86pts vs SPY over 30 days), suggesting the dip is at least partly sector-wide rather than idiosyncratic (+1). No hard veto conditions are present: no imminent earnings, no SEC filings flagging deterioration, no fundamental red flags. Macro is modestly constructive — VIX at the 19th percentile (low fear, no elevated-VIX penalty), the 2s10s spread is positive (+0.46pp, no inversion headwind), and the 10Y at 4.45% is just below the 4.5% headwind threshold (neutral for a defensive/value health-care name). No insider activity or unusual options flow were present to score positively or negatively. Starting from the ~57.5% base-rate anchor for a 15%+ dip without fundamental impairment, the +3 net score supports a modest upward adjustment, tempered by thin confirming signals (no insider buys, no unusual call flow, negative sector flow proxy today).
- ✓Jun 1, 7:03 AMdecisionacted
Agent 5 — Dip Buyer (Evolving) — decide: buy
Net signal score: +3. TECH (Bio-Techne) is down 17.3% from its 30-day high — a drop magnitude >=15% without any identified fundamental cause (+1 mean-reversion candidate). No earnings are visible within the 90-day window (+1 clean runway). The Health Care sector is underperforming the market (30d rel-strength rank 3/11 but down 5.86pts vs SPY over 30 days), suggesting the dip is at least partly sector-wide rather than idiosyncratic (+1). No hard veto conditions are present: no imminent earnings, no SEC filings flagging deterioration, no fundamental red flags. Macro is modestly constructive — VIX at the 19th percentile (low fear, no elevated-VIX penalty), the 2s10s spread is positive (+0.46pp, no inversion headwind), and the 10Y at 4.45% is just below the 4.5% headwind threshold (neutral for a defensive/value health-care name). No insider activity or unusual options flow were present to score positively or negatively. Starting from the ~57.5% base-rate anchor for a 15%+ dip without fundamental impairment, the +3 net score supports a modest upward adjustment, tempered by thin confirming signals (no insider buys, no unusual call flow, negative sector flow proxy today).
- ✓May 29, 6:03 PMdecisionacted
options_momentum — decide: buy
CALL on TECH — 5-day return 9.10% with close above 20-day MA ($48.58). IV 82.2%. Sized 1 contract(s) at $5.19 premium.
- ?May 29, 7:02 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $3.04 cash available; close=$50.84.
- !May 29, 7:02 AMsignal
Agent 5 — Dip Buyer (Evolving) — insufficient_capital
Net signal score: +2. Positive signals fired for (1) drop magnitude ≥15% from 30-day high without any identifiable fundamental cause (no SEC filings, no headlines, no guidance cuts), and (2) no earnings within 30 days, providing a clean 90-day runway. The sector (Health Care / XLV) shows modest positive 5-day relative strength vs SPY (+0.75pts) and today's sector flow proxy is strongly positive (+21.7M), suggesting the drop may be idiosyncratic noise rather than systemic deterioration. Macro context is benign: VIX at 46th percentile is neutral, the yield curve is positively sloped (+49bps 2s10s), and broad market tone today is constructive (SPY +0.55%, VXX -1.84%). No insider activity, options flow, or fundamental filings were available to add conviction in either direction. The base-rate anchor of ~55-60% for a ≥15% dip recovery in 90 days with no fundamental impairment, combined with the net +2 score and clean macro, supports a modest buy with probability calibrated to the low end of the +2 range given the near-total absence of confirmatory microstructure signals.
- ✓May 29, 7:01 AMdecisionacted
options_momentum — decide: buy
CALL on TECH — 5-day return 8.87% with close above 20-day MA ($48.76). IV 85.3%. Sized 2 contract(s) at $5.37 premium.
- ▢May 28, 8:00 PMjournal
options_momentum opened long 100 @ $5.19
- ?May 28, 6:01 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $12.25 cash available; close=$48.09.
- !May 28, 6:01 PMsignal
Agent 5 — Dip Buyer (Evolving) — insufficient_capital
Wanted to buy but only $1.29 cash available; close=$48.09.
- ?May 28, 6:01 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
The 28.9% drop from the 30-day high is severe, but available news does not indicate fundamental deterioration — there are no guidance cuts, accounting issues, or sector collapse signals. Bio-Techne recently had an earnings call (Q1) and passed a qualitative screening filter, suggesting the business remains operationally intact. However, the macro context shows elevated 10-year inflation expectations (2.4σ above trend), which creates meaningful headwinds for long-duration, growth-oriented life sciences names like TECH, and the absence of recent SEC filings leaves uncertainty about the Q1 earnings details that may have triggered the sell-off.
- !May 28, 6:01 PMsignalseverity 0.23
Agent 4 — Dip Buyer (Frozen) — dip_skipped
The 28.9% drop from the 30-day high is severe, but available news does not indicate fundamental deterioration — there are no guidance cuts, accounting issues, or sector collapse signals. Bio-Techne recently had an earnings call (Q1) and passed a qualitative screening filter, suggesting the business remains operationally intact. However, the macro context shows elevated 10-year inflation expectations (2.4σ above trend), which creates meaningful headwinds for long-duration, growth-oriented life sciences names like TECH, and the absence of recent SEC filings leaves uncertainty about the Q1 earnings details that may have triggered the sell-off.
- ?May 28, 11:11 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
TECH is up 4.02% intraday with no headline catalyst, suggesting this is flow/positioning-driven rather than news-driven. The move is meaningful in magnitude and represents real conviction from someone with size. However, several factors temper enthusiasm: (1) With 275 minutes remaining (~4.6 hours), there is ample time but also ample time for a fade or consolidation after a 4% move — late-session profit-taking is common after a gap/surge of this size. (2) The macro backdrop shows T10Y3M at 1.8σ above trend, indicating a steepening yield curve that is net neutral-to-mildly positive for growth/tech names (not a headwind, but not a tailwind either). (3) No news confirms a fundamental catalyst, which slightly increases fade risk relative to a news-driven move. (4) No reversal pattern is evident from the data provided, and absence of news is not disqualifying. On balance, the default lean is continuation given the system's asymmetric payoff structure (bounded downside via stops, fixed upside target), but the setup is ordinary momentum without strong confirming signals, placing this in the 0.5–0.65 range.
- !May 28, 11:11 AMsignalseverity 0.04
Agent 7 — Day Trader — day_trade_skipped
TECH is up 4.02% intraday with no headline catalyst, suggesting this is flow/positioning-driven rather than news-driven. The move is meaningful in magnitude and represents real conviction from someone with size. However, several factors temper enthusiasm: (1) With 275 minutes remaining (~4.6 hours), there is ample time but also ample time for a fade or consolidation after a 4% move — late-session profit-taking is common after a gap/surge of this size. (2) The macro backdrop shows T10Y3M at 1.8σ above trend, indicating a steepening yield curve that is net neutral-to-mildly positive for growth/tech names (not a headwind, but not a tailwind either). (3) No news confirms a fundamental catalyst, which slightly increases fade risk relative to a news-driven move. (4) No reversal pattern is evident from the data provided, and absence of news is not disqualifying. On balance, the default lean is continuation given the system's asymmetric payoff structure (bounded downside via stops, fixed upside target), but the setup is ordinary momentum without strong confirming signals, placing this in the 0.5–0.65 range.
- ?May 28, 10:16 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
TECH is up 3.49% intraday, which represents meaningful real flow and conviction from size participants. No headlines are present, but absence of news does not disqualify — this move reflects genuine buying pressure. With 330 minutes remaining (essentially a full trading day still ahead, suggesting this is an early-session read), there is ample time for continuation. However, several factors temper enthusiasm: (1) The macro context shows T10Y3M at 1.8σ above its 24-month trend, signaling a steeper yield curve environment that can pressure growth/tech names as rate expectations shift — this is a mild headwind for TECH-sector continuation. (2) No catalyst is identifiable to sustain the move or attract additional buyers into the close. (3) The 3.49% move is already at the upper end of the 2-5% range, meaning a portion of near-term upside may already be captured. Balancing strong initial momentum and ample time remaining against macro headwinds and no identifiable catalyst, this is an ordinary momentum setup — probability sits just above the 0.5 threshold, warranting a long position with disciplined stop and target management.
- !May 28, 10:16 AMsignalseverity 0.03
Agent 7 — Day Trader — day_trade_skipped
TECH is up 3.49% intraday, which represents meaningful real flow and conviction from size participants. No headlines are present, but absence of news does not disqualify — this move reflects genuine buying pressure. With 330 minutes remaining (essentially a full trading day still ahead, suggesting this is an early-session read), there is ample time for continuation. However, several factors temper enthusiasm: (1) The macro context shows T10Y3M at 1.8σ above its 24-month trend, signaling a steeper yield curve environment that can pressure growth/tech names as rate expectations shift — this is a mild headwind for TECH-sector continuation. (2) No catalyst is identifiable to sustain the move or attract additional buyers into the close. (3) The 3.49% move is already at the upper end of the 2-5% range, meaning a portion of near-term upside may already be captured. Balancing strong initial momentum and ample time remaining against macro headwinds and no identifiable catalyst, this is an ordinary momentum setup — probability sits just above the 0.5 threshold, warranting a long position with disciplined stop and target management.
- ?May 28, 7:01 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $1.29 cash available; close=$48.09.
- !May 28, 7:01 AMsignal
Agent 5 — Dip Buyer (Evolving) — insufficient_capital
Wanted to buy but only $0.00 cash available; close=$47.97.
- ?May 27, 6:01 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $0.00 cash available; close=$47.97.
- ?May 27, 6:01 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
The 28.9% drop from the 30-day high is severe, but available news does not indicate fundamental deterioration — there are no guidance cuts, accounting issues, or sector collapse signals. Bio-Techne recently had an earnings call (Q1) and passed a qualitative screening filter, suggesting the business remains operationally intact. However, the macro context shows elevated 10-year inflation expectations (2.4σ above trend), which creates meaningful headwinds for long-duration, growth-oriented life sciences names like TECH, and the absence of recent SEC filings leaves uncertainty about the Q1 earnings details that may have triggered the sell-off.
- !May 27, 6:01 PMsignalseverity 0.23
Agent 4 — Dip Buyer (Frozen) — dip_skipped
The 28.9% drop from the 30-day high is severe, but available news does not indicate fundamental deterioration — there are no guidance cuts, accounting issues, or sector collapse signals. Bio-Techne recently had an earnings call (Q1) and passed a qualitative screening filter, suggesting the business remains operationally intact. However, the macro context shows elevated 10-year inflation expectations (2.4σ above trend), which creates meaningful headwinds for long-duration, growth-oriented life sciences names like TECH, and the absence of recent SEC filings leaves uncertainty about the Q1 earnings details that may have triggered the sell-off.
- !May 27, 6:01 PMsignal
Agent 5 — Dip Buyer (Evolving) — insufficient_capital
Wanted to buy but only $0.00 cash available; close=$47.97.
- ✓May 27, 6:01 PMdecisionacted
Agent 8 — Dip Buyer (Peer-Aware) — decide: buy
Wanted to buy but only $0.00 cash available; close=$48.21.
- ?May 27, 7:01 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $0.00 cash available; close=$47.97.
- !May 27, 7:01 AMsignal
Agent 5 — Dip Buyer (Evolving) — insufficient_capital
Wanted to buy but only $22.31 cash available; close=$48.21.
- ✓May 27, 7:01 AMdecisionacted
Agent 8 — Dip Buyer (Peer-Aware) — decide: buy
Wanted to buy but only $0.00 cash available; close=$48.21.
- ▢May 26, 8:00 PMjournal
Agent 8 — Dip Buyer (Peer-Aware) opened long 15 @ $49.52
- ▢May 26, 8:00 PMjournal
Agent 8 — Dip Buyer (Peer-Aware) opened long 16 @ $49.52
- ?May 26, 6:01 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
The 28.9% drop from the 30-day high is severe, but available news does not indicate fundamental deterioration — there are no guidance cuts, accounting issues, or sector collapse signals. Bio-Techne recently had an earnings call (Q1) and passed a qualitative screening filter, suggesting the business remains operationally intact. However, the macro context shows elevated 10-year inflation expectations (2.4σ above trend), which creates meaningful headwinds for long-duration, growth-oriented life sciences names like TECH, and the absence of recent SEC filings leaves uncertainty about the Q1 earnings details that may have triggered the sell-off.
- ?May 26, 6:01 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $22.31 cash available; close=$48.21.
- !May 26, 6:01 PMsignalseverity 0.23
Agent 4 — Dip Buyer (Frozen) — dip_skipped
The 28.9% drop from the 30-day high is severe, but available news does not indicate fundamental deterioration — there are no guidance cuts, accounting issues, or sector collapse signals. Bio-Techne recently had an earnings call (Q1) and passed a qualitative screening filter, suggesting the business remains operationally intact. However, the macro context shows elevated 10-year inflation expectations (2.4σ above trend), which creates meaningful headwinds for long-duration, growth-oriented life sciences names like TECH, and the absence of recent SEC filings leaves uncertainty about the Q1 earnings details that may have triggered the sell-off.
- !May 26, 6:01 PMsignal
Agent 5 — Dip Buyer (Evolving) — insufficient_capital
Wanted to buy but only $0.00 cash available; close=$48.21.
- ✓May 26, 6:01 PMdecisionacted
Agent 8 — Dip Buyer (Peer-Aware) — decide: buy
Wanted to buy but only $0.00 cash available; close=$48.21.
- ?May 26, 7:03 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $0.00 cash available; close=$48.21.
- !May 26, 7:03 AMsignal
Agent 5 — Dip Buyer (Evolving) — insufficient_capital
Net signal score: +1. Positive signals: drop magnitude >=15% from 30-day high without an identifiable fundamental cause (+1), no earnings in visible window (+1), sector showing modest 5-day outperformance vs SPY (+2.43pts) suggesting the drop may be somewhat idiosyncratic but not catastrophically so. Negative signals: Health Care sector is a weak performer (rank 7 of 11, -7.99pts vs SPY on 30d basis) which partially offsets the drop-as-mean-reversion thesis; 10Y yield at 4.57% is above the ~4.5% threshold and represents a structural headwind for growth-sensitive names (-1); no insider buying, no options flow, and no SEC filings leave the thesis data-sparse. The net score of +1 is marginal with no strong anchor signal (no cluster buy, no unusual call flow), so conviction remains low. The 22.8% drawdown is significant and supports mean-reversion at the base rate, but the lack of any confirming signals keeps probability near the lower end of the marginal range.
- ?May 26, 7:02 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip_no_cash
Wanted to buy but only $0.00 cash available; close=$48.21.
- ?May 22, 6:01 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
STEP 1 — No hard veto fires outright: no imminent earnings visible, no 10-Q/8-K with guidance cuts or going-concern language, and while Health Care is a weak sector it is not in freefall (week-over-week sector data does not confirm >5% weekly drop with simultaneous credit stress). STEP 2 — Signal scoring: POSITIVE: (1) Drop magnitude >=15% from 30-day high without confirmed fundamental cause (+1, mean-reversion candidate — 30.7% decline is substantial); (2) Sector is underperforming market — XLV ranks 10 of 11 by 30-day relative strength, -13.87pts vs SPY over 30 days, suggesting the dip is at least partly sector-wide rather than purely idiosyncratic (+1); (3) No earnings within visible window (+1, clean runway). NEGATIVE: (1) No insider buying activity whatsoever in 30 days — with a 30.7% decline, the complete absence of insider buying is a meaningful warning signal that insiders are not viewing this as a bargain (-1); (2) No options flow data to confirm unusual call activity — cannot score the positive signal, and absence of confirming flow is a soft negative (0, neutral but removes a potential +1); (3) Sector flow proxy is deeply negative today at -13.8M, compounding the sector weakness on a broadly risk-off day (-1); (4) 10Y yield at 4.47% is approaching but not exceeding 4.5% threshold — marginal headwind for a health-care biotech name, scoring neutral (0); (5) T5YIE at 2.7%, 2.5σ above 24-month trend signals elevated inflation expectations, a headwind for growth-oriented biotech names (-1); (6) Broad market tone is negative today (SPY -1.20%, IWM -2.41%, QQQ -1.51%) adding near-term momentum headwind (soft -0.5, rounded to 0 as macro tone is already reflected in sector flow signal). NET SCORE: +3 positives, -3 negatives = 0. A net score of 0 is marginal and per framework requires the single strongest positive to be a cluster insider buy or unusual call flow to justify a buy — neither is present. The absence of insider buying into a 30.7% drawdown is particularly concerning as a signal that those with the most information are not stepping in. Without a confirming insider or options signal, a net-zero score on a 30% drop stock in the weakest sector cohort does not clear the bar. STEP 3 — No hard veto but net score of 0 without the required confirming insider/options catalyst → sound=false. STEP 4 — Anchoring at 55-60% base rate, adjusted down for: zero insider buying signal (-8%), deeply negative sector flow and sector rank 10/11 (-5%), elevated inflation expectations as headwind for growth health care (-4%), net neutral signal score with no positive catalyst to anchor the thesis (-5%). Final estimate: ~38%.
- ?May 22, 6:01 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
The 28.9% drop from the 30-day high is severe, but available news does not indicate fundamental deterioration — there are no guidance cuts, accounting issues, or sector collapse signals. Bio-Techne recently had an earnings call (Q1) and passed a qualitative screening filter, suggesting the business remains operationally intact. However, the macro context shows elevated 10-year inflation expectations (2.4σ above trend), which creates meaningful headwinds for long-duration, growth-oriented life sciences names like TECH, and the absence of recent SEC filings leaves uncertainty about the Q1 earnings details that may have triggered the sell-off.
- ?May 22, 6:01 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
Bio-Techne (TECH) has fallen 30.7% from its 30-day high with no confirmed fundamental impairment — no negative earnings surprise, no guidance cut, and no insider selling visible in the filings. The stock passed the "Caviar Cruise Screen" per recent news, suggesting some analyst-level quality recognition. However, the sector (Health Care / XLV) is the 2nd worst performer in relative strength over 30 days (-13.87pts vs SPY), indicating the drop is at least partly sector-driven, which could persist. The macro backdrop is mixed: VIX is at the 50th percentile (not alarming), but 5-year inflation expectations are running 2.5σ above trend (a structural headwind for growth-oriented biotech tools names), and today's broad market is under pressure across all benchmarks. With no insider cluster buys, no unusual options call flow, no visible earnings catalyst, and heavy sector-wide selling pressure, confirmation signals are absent despite the lack of a clear fundamental break.
- ?May 22, 3:30 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
TECH is up 1.55% today, which is a modest but real move. However, with only 15 minutes remaining until the forced 3:45 PM ET close, there is minimal time for the trend to extend meaningfully toward the +3% profit target. The macro context (T10Y3M at 2.2σ above trend) is not directly bearish for a generic tech name but does signal a steepening/risk environment that is sector-neutral to mildly unfavorable. No headlines provide a catalyst to sustain buying pressure. At this point in the session, end-of-day profit-taking and position flattening are common, creating a slight headwind. The move magnitude (1.55%) is below the 2-5% threshold that would itself constitute strong conviction evidence. With the time constraint being the dominant factor — 15 minutes is insufficient for a +3% target to be hit and creates meaningful risk of a fade into the close — this setup does not clear the continuation threshold.
- ▣May 19, 8:00 PMjournalstop
options_momentum closed long 200 @ $3.95 (-$153.38)
Stop: premium $3.95 ≤ trailing floor $4.02 (peak $5.36 × 0.75)
- ▢May 13, 8:00 PMjournal
options_momentum opened long 200 @ $4.72